# Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

> **NCT06446206** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Hospital of Jilin University** · enrollment: 22 (estimated)

## Conditions studied

- Platinum-sensitive Relapsed Ovarian Cancer

## Interventions

- **DRUG:** Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib

## Key facts

- **NCT ID:** NCT06446206
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06
- **Primary completion:** 2026-06
- **Final completion:** 2028-06
- **Target enrollment:** 22 (ESTIMATED)
- **Last updated:** 2024-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06446206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06446206, "Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06446206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*